MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-10-2022
Genmab A/S Revenue 2011-2026 | GMAB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Genmab A/S
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 10.1 B | 5.37 B | 3.03 B | 2.37 B | 1.82 B | 1.13 B | 850 M | 664 M | 485 M | 351 M |
All numbers in DKK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 B | 351 M | 2.62 B |
Quarterly Revenue Genmab A/S
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 1.97 B | - | - | - | 5.45 B | - | - | - | 774 M | - | - | - | 510 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in DKK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.45 B | 510 M | 2.18 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.82 | -3.48 % | $ 4.47 M |  China |
 |
Rigel Pharmaceuticals
RIGL
|
294 M | $ 33.23 | -4.03 % | $ 584 M |  USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
1 B | $ 20.15 | -2.68 % | $ 2.54 B | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
42.3 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
638 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
BridgeBio Pharma
BBIO
|
502 M | $ 64.66 | -1.37 % | $ 12.4 B | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 8.52 | -2.46 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
31.1 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | USA |
 |
Certara
CERT
|
419 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
41 K | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
1 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
149 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
25.2 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
589 M | $ 24.0 | 0.5 % | $ 2.93 B | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
59.3 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
53.9 M | - | - | $ 1.2 B | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
43 K | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43 K | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
163 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
Denali Therapeutics
DNLI
|
331 M | $ 20.02 | -4.67 % | $ 3.29 B | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Eton Pharmaceuticals
ETON
|
31.6 M | $ 17.54 | -3.36 % | $ 450 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
7 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
18.2 M | - | 7.55 % | $ 38.1 M | USA |